Today's biotech news includes FTC declining to challenge Novo-Catalent deal, an unusual gene therapy approach, and more.

STAT

Boston

Suffolk County

Massachusetts

United States

Viridian confirms benefit of drug for thyroid eye disease

Viridian Therapeutics stock popped Monday after the company scored a win in thyroid eye disease, a condition that causes the eyes to swell. The post Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen appeared first on Investor's Business Daily.

All Sides

Media Bias/Fact Check

Investor's Business Daily

Biotech Surges 24% After Crushing Amgen In Eye Disease

Ad Fontes Media

The Boston Globe

By Mariam Sunny (Reuters) -Viridian Therapeutics’ experimental treatment for chronic thyroid eye disease (TED) significantly reduced symptoms such as double vision and eye bulging in a late-stage study, sending its shares surging more than 26%. The success of the antibody drug, veligrotug, follows a separate late-stage study in September where it helped reduce symptoms in patients with active or early phase of the immune system condition. TED ca…

regionalmedianews.com

Viridian shares soar after latest trial success for thyroid eye disease drug - Regional Media News

As December 16, 2024 approaches, all eyes will be on Viridian Therapeutics, Inc. (NASDAQ: VRDN) as the biopharmaceutical company prepares to unveil the topline results from its THRIVE-2 Phase 3 clinical trial evaluating its promising product, veligrotug, for the treatment of chronic Thyroid Eye Disease (TED). This pivotal moment represents a crucial juncture for Viridian, as success in this trial could significantly bolster the company's positio…

csimarket.com

#Viridian Therapeutics Poised for Impact Amid Mixed Clinical Trial and Revenue Developments

A phase 3 clinical trial of veligrotug, an anti-insulin-like growth factor-1 receptor antibody, showed improvements in proptosis, clinical activity scores, and diplopia for chronic thyroid eye disease. The trial involved 188 patients, with those receiving veligrotug showing a higher proptosis responder rate, mean reduction in proptosis, and diplopia response compared to the placebo group. Veligrotug was well tolerated, with the majority of adver…

Dataemia

All endpoints achieved in phase 3 trial of chronic thyroid eye disease treatment

Amgen

Biotech

Stock Markets

Science

Viridian confirms benefit of drug for thyroid eye disease

Coverage Details

Give the gift of Perspective

Bias Distribution

Ownership

Similar News Topics

Similar News Topics